Galera Therapeutics Inc Ordinary Shares Financials - Benzinga

Galera Therapeutics Inc Ordinary Shares

GRTXOTC

Trade with Public

Trade with Public

$0.0880

-28.91-99.7%

Last update: Jul 10, 3:39 PM

Overview News Earnings Forecast Price TargetsFinancialsSentiment Ownership Compare

Galera Therapeutics Inc Ordinary Shares Financials

Galera Therapeutics Inc Ordinary Shares (GRTX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Galera Therapeutics Q1 EPS $(0.01), Same YoY

Galera Therapeutics (NASDAQ:GRTX) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year.

Benzinga Newsdesk

PRO
Galera Therapeutics Q3 EPS $(0.01) Up From $(0.10) YoY

Galera Therapeutics (NASDAQ:GRTX) reported quarterly losses of $(0.01) per share. This is a 90 percent increase over losses of $(0.10) per share from the same period last year.

Benzinga Newsdesk

PRO
Galera Therapeutics Q1 EPS $(0.01) Up From $(0.08) YoY

Galera Therapeutics (NASDAQ:GRTX) reported quarterly losses of $(0.01) per share. This is a 87.5 percent increase over losses of $(0.08) per share from the same period last year.

Benzinga Newsdesk

PRO
Galera Therapeutics Had Cash And Cash Equivalents Of $13.5M Expected To Provide Cash Runway Into Q3 2025

Benzinga Newsdesk

PRO
Galera Therapeutics Q1 2024 GAAP EPS $(0.08) Beats $(0.35) Estimate

Benzinga Newsdesk

Galera Therapeutics: Q4 Earnings Insights

Benzinga Insights